- Company
- Generic companies seek early entry into KRW 100 bil Tagrisso
- by Kim, Jin-Gu Nov 12, 2024 05:51am
- Patent challenges to Tagrisso (osimertinib), a non-small cell lung cancer treatment that posts annual sales of KRW 110 billion, are expanding.&160; The companies that have filed patent challenges seek to first evade the product patent, which expires in 2035, and then launch generics early after November 2033, when the substance patent ex
- Company
- Will Lorviqua be reimbursed as a first-line therapy in KOR?
- by Eo, Yun-Ho Nov 11, 2024 05:49am
- Whether progress will be made in the insurance reimbursement discussions for the ALK antitumor drug Lorviqua is gaining attention. The health authorities recently said they would “promptly start discussions” on the need to expand coverage of the ALK-positive NSCLC drug Lorviqua (lorlatinib) to the first-line. Lorviqua is currently in
- Company
- Companies copromote products at Hypertension Seoul 2024
- by Kim, Jin-Gu Nov 11, 2024 05:49am
- Pharmaceutical and biotech companies with hypertension drugs have gathered at the Conrad Seoul Hotel in Yeouido, Seoul on the 8th. Industry officials, who set up promotional booths at the Korean Society of Hypertension's fall conference (Hypertension Seoul 2024), distributed pamphlets to doctors at the event and introduced the features of t
- Company
- 'Voranigo' for malignant brain tumor expected to land in KOR
- by Eo, Yun-Ho Nov 11, 2024 05:49am
- 'Voranigo,' a new therapy for malignant brain tumors in over twenty years, is anticipated to be brought to South Korea. Sources said that Servier has recently filed an approval application for Voranigo (vorasidenib). Earlier in September, the Ministry of Food and Drug Safety (MFDS) assigned Voranigo an Orphan Drug Designation (ODD).
- Company
- K-Bios showcases new ADC drugs on the international stage
- by Son, Hyung Min Nov 11, 2024 05:49am
- The domestic pharma and biotech industry is speeding up the development of new antibody-drug conjugates (ADCs), unveiling their clinical results. At the 'World ADC 2024' that was held in San Diego, U.S. for 4 days from the 4th of this month, domestic pharmaceutical bio companies including Celltrion, LigaChem Biosciences, and ABL Bio revealed
- Company
- 20-valent pneumococcal conjugate vaccine to enter market
- by Whang, byung-woo Nov 8, 2024 05:47am
- The pneumococcal vaccine market, which has shifted with the introduction of a 15-valent vaccine this year, is expected to again face fierce competition with the approval of a new 20-valent vaccine. Pfizer, which is about to launch a new product, plans to replace the share of its existing product, Prevenar 13 with its new product, Prevenar 20
- Company
- Optivo's clinical results for Koreans with gastric cancer
- by Son, Hyung Min Nov 8, 2024 05:47am
- Optivo, an immunotherapy used to treat certain types of cancer, showed a positive result in gastric cancer clinical trials that involved Koreans. The study demonstrated a 47% reduction in the disease progression and death risk compared to conventional therapies. According to industry sources on November 6th, Bristol Myers Squibb (BMS) and
- Company
- Geo-Young and UBC Korea sign MOU to distribute Bimzelx
- by Son, Hyung Min Nov 8, 2024 05:47am
- Geo-Young announced today that it has signed a Memorandum of Understanding with UBC Korea to distribute Bimzelx. Under the agreement, Geo-Young will carry out the entire distribution process from storage to supply of Bimzelx. Bimzelx is a treatment for plaque psoriasis that simultaneously and directly targets and inhibits interleukin
- Company
- Novo Nordisk tops KRW 14T in sales, thanks to Wegovy
- by Whang, byung-woo Nov 8, 2024 05:46am
- Novo Nordisk has recorded a strong sales performance in Q3, driven by the steady growth of its major products, including Wegovy and Ozempic. According to Novo Nordisk's business reports on November 6th (local time), they recorded US$10.267 billion (KRW 14.3378 trillion) in Q3 sales, up 21% from the previous year. Its operating profit a
- Company
- Oral psoriasis drug 'Sotyktu' lands at Big 5 hospitals
- by Son, Hyung Min Nov 8, 2024 05:46am
- Oral psoriasis drug 'Sotyktu' is now available for prescription at tertiary general hospitals. According to industry sources, BMS Korea’s TYK2 inhibitor, Sotyktu (deucravacitinib), has passed the drug committees of the 'Big 5' tertiary hospitals, including Samsung Medical Center, Seoul University Hospital, Seoul St. Mary's Hospital, Seoul
